HeXun Biosciences CoROCO:6986 23 Current Ratio is 9.75 as of Dec. 2025, which is 4% below its 10-year median of 10.15. GuruFocus rates ROCO:6986 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, HeXun Biosciences Co ranks better than 77.04% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. HeXun Biosciences Co's current ratio for the quarter that ended in Dec. 2025 was 9.75.
HeXun Biosciences Co has a current ratio of 9.75. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for HeXun Biosciences Co's Current Ratio or its related term are showing as below:
ROCO:6986'
s Current Ratio Range Over the Past 10 Years
Min: 6.67 Med: 10.15 Max: 12.05
Current: 9.75
During the past 6 years, HeXun Biosciences Co's highest Current Ratio was 12.05. The lowest was 6.67. And the median was 10.15.
ROCO:6986's Current Ratio is ranked better than 77.04% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs ROCO:6986: 9.75
HeXun Biosciences Co (ROCO:6986) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
HeXun Biosciences Co Current Ratio Related Terms
HeXun Biosciences Co Current Ratio Historical Data
* Premium members only.
The historical data trend for HeXun Biosciences Co's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6986 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, HeXun Biosciences Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co (ROCO:6986) has a Current Ratio of 9.75 as of Dec. 2025. This is near median its historical median of 10.15. Over the past decade, HeXun Biosciences Co's Current Ratio has ranged from 6.67 to 12.05. According to the industry distribution chart, HeXun Biosciences Co ranks #324 out of 1411 companies in the Biotechnology industry, placing it in the top 23%.
Is HeXun Biosciences Co's Current Ratio too high?
HeXun Biosciences Co's current Current Ratio of 9.75 is near median its 10-year median of 10.15. Over the past 10 years, this metric has ranged from a low of 6.67 to a high of 12.05. The Biotechnology industry median Current Ratio is 3.88. HeXun Biosciences Co's value of 9.75 is 151.3% above this industry median. Based on the distribution chart, HeXun Biosciences Co ranks #324 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #324 out of 1411 companies for Current Ratio. This places HeXun Biosciences Co in the top 23% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. HeXun Biosciences Co's value of 9.75 is 151.3% above this benchmark. Historically, HeXun Biosciences Co's own Current Ratio has ranged from 6.67 to 12.05 over the past decade. While the company's 10-year median is 10.15 vs. the industry median of 3.88, HeXun Biosciences Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeXun Biosciences Co's current Current Ratio of 9.75 is 151.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeXun Biosciences Co's current Current Ratio is 9.75, which is near median its own 10-year median of 10.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current Current Ratio of 9.75. The current Current Ratio is 9.75, which is near median its 10-year median of 10.15 and 151.3% above the Biotechnology industry median of 3.88. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Current Ratio is 9.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score
Get the complete analysis for ROCO:6986
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
